Clinical Trial

Effects of EXOPULSE Mollii Suit on Spasticity and Functionality in Multiple Sclerosis Patients

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Spasticity affects \>80% of MS patients, with 35-54% experiencing moderate-to-severe symptoms, impairing mobility and sleep. Electrical stimulation parameters (e.g., high vs. low frequency) for spasticity management remain debated. The EXOPULSE Mollii Suit uses non-invasive, low-frequency stimulation to induce reciprocal inhibition and modulate spinal interneuron activity, potentially reducing spasticity. This study aims to compare EXOPULSE Mollii + exercise vs. EXOPULSE Mollii alone in improving spasticity and function in MS.
Trial Details
NCT Number NCT07126730
Lead Sponsor Hacettepe University
Conditions Multiple Sclerosis
Enrollment 30 participants
Start Date 2025-09-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-17